公开(公告)号：US20050267045A1

公开(公告)日：2005-12-01

申请号：US11093950

申请日：2005-03-29

申请人： Toshio Miyata

发明人： Toshio Miyata

IPC分类号： A61K31/155 ,  A61M1/28 ,  A61K31/70 ,  A61K31/33

CPC分类号： A61K31/203 ,  A61K31/155 ,  A61K31/4965 ,  A61K33/00 ,  A61M1/287 ,  Y10S514/832 ,  Y10S514/866 ,  A61K2300/00

摘要： Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.

摘要翻译： 产生并积累在腹膜透析液中的羰基化合物可以被羰基化合物捕获剂如氨基胍灭活或消除。 消毒和储存腹膜透析液期间产生的羰基化合物可以通过与捕获剂预接触来消除。 此外，通过将腹膜透析液中的捕获剂添加到通过羰基化合物捕获筒的循环中，可以消除腹膜透析治疗期间从血液转移到患者腹膜的羰基化合物。 通过羰基化合物的腹膜内蛋白质修饰被本发明抑制，从而充分减少与腹膜透析治疗相关的腹膜障碍。

公开(公告)号：US20050058724A1

公开(公告)日：2005-03-17

申请号：US10721501

申请日：2003-11-26

申请人： Richard Veech

发明人： Richard Veech

IPC分类号： A61K31/19 ,  A61K33/06 ,  A61K33/10 ,  A61K33/14 ,  A61M1/16 ,  A61M1/28 ,  C12N5/00 ,  A01N59/08

CPC分类号： A61K33/06 ,  A61K31/19 ,  A61K33/10 ,  A61K33/14 ,  A61M1/1654 ,  A61M1/287 ,  C12N5/0018 ,  C12N2500/12 ,  A61K33/00 ,  A61K2300/00

摘要： Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

摘要翻译： 提供电解质溶液，其可用于电解质和流体疗法，肠外营养和透析。 将Na：Cl比值归一化，血浆和细胞pH值被归一化，并且细胞辅因子比率以与现有技术溶液相比降低毒性的方式进行归一化。

公开(公告)号：US06779468B1

公开(公告)日：2004-08-24

申请号：US09341032

申请日：1999-09-08

申请人： Ajay Gupta

发明人： Ajay Gupta

IPC分类号： B01D1100

CPC分类号： A61K33/26 ,  A61M1/1654 ,  A61M1/287

摘要： A method of administering iron to dialysis patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis or peritoneal dialysis solutions, by the process of dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidal ferric compound, preferably ferric pyrophosphate.

摘要翻译： 通过渗透过程输注可溶于血液透析或腹膜透析溶液的非胶体铁化合物来实现向透析患者施用铁的方法。 提供的药物组合物基本上由透析溶液组成，该溶液包括可溶性非胶体铁化合物，优选焦磷酸铁。

公开(公告)号：US20030225066A1

公开(公告)日：2003-12-04

申请号：US10160529

申请日：2002-05-31

申请人： Biolink Corporation

发明人： Hans-Dietrich Polaschegg

IPC分类号： A61K031/549 ,  A61K031/19 ,  C02F001/44

CPC分类号： A61K31/19 ,  A61K31/549 ,  A61M1/287

摘要： The present invention contemplates the addition of 0.5% to 4% taurolidine into solutions used peritoneal dialysis. The taurolidine is intended to prevent or reduce the incidence of infection within the abdomen and/or in the vicinity of an implanted dialysis port. The invention also includes methods using solutions of taurolidine in the flushing and locking of catheters and fluid lines used in peritoneal dialysis.

摘要翻译： 本发明考虑将0.5％至4％的taurolidine加入到腹膜透析溶液中。 该taurolidine旨在防止或减少在腹部和/或植入的透析口附近的感染的发生率。 本发明还包括使用taurolidine的溶液在用于腹膜透析的导管和流体管线的冲洗和锁定中的方法。

公开(公告)号：US06492336B1

公开(公告)日：2002-12-10

申请号：US09463758

申请日：2000-06-08

申请人： Arezki Mahiout

发明人： Arezki Mahiout

IPC分类号： A61K3314

CPC分类号： A61M1/287 ,  A61K33/14 ,  A61K33/10 ,  A61K33/00 ,  A61K31/70 ,  A61K2300/00

摘要： Peritoneal dialysis fluids and the use thereof for performing peritoneal dialysis are disclosed. The peritoneal dialysis fluid comprises a physiologically acceptable aqueous solution containing physiologically acceptable inorganic anions and cations and, as an osmotic agent, at least one sugar derivative, at concentrations sufficient for the removal of water and solutes from a patient by peritoneal dialysis. The sugar derivative is a compound of formula wherein each SG, which may be the same or different, represents a residue of a physiologically acceptable metabolizable sugar, SA represents a residue of a physiologically acceptable metabolizable sugar alcohol, n is from 1 to 4 and represents a glycoside linkage which is cleavable by an &agr;-glycosidase enzyme.

摘要翻译： 公开了腹膜透析液及其用于进行腹膜透析的用途。 腹膜透析液包含生理上可接受的含有生理上可接受的无机阴离子和阳离子的水溶液，以及作为渗透剂的至少一种糖衍生物，其浓度足以通过腹膜透析从患者中除去水和溶质。 糖衍生物是每种SG的化合物，其可以相同或不同，代表生理上可接受的可代谢糖的残基，SA表示生理上可接受的可代谢糖醇的残基，n为1至4，并且表示糖苷 可通过α-糖苷酶切割的连接。

公开(公告)号：US06429294B1

公开(公告)日：2002-08-06

申请号：US09334893

申请日：1999-06-17

申请人： Toshiaki Masuda ,  Hidetoshi Yamamoto

发明人： Toshiaki Masuda ,  Hidetoshi Yamamoto

IPC分类号： A61M114

CPC分类号： A61M1/287 ,  A61M1/1696 ,  A61M1/284

摘要： A peritoneal dialysis fluid used for a continuous recirculating peritoneal dialysis wherein the peritoneal dialysis fluid is infused into a peritoneal cavity of a patient and then, typically on a continuous process basis a portion of the dialysis fluid is sequentially drained from the cavity, cleansed through an extracorpreal dialyzer, and reinfused into the cavity. The dialysis fluid contains as an osmotic agent a substance which does not substantially permeate through pores of hollow fiber membrane of an extracorporeal dialyzer, preferably an osmotic agent having a molecular weight of about 20,000 to about 100,000. The supplemented amount of the osmotic agent is reduced or not needed during the dialysis.

摘要翻译： 用于连续循环腹膜透析的腹膜透析液，其中将腹膜透析液注入患者的腹膜腔，然后通常在连续过程的基础上将部分透析液从腔中顺次排出，通过 体外透析液，并重新灌注到腔内。 透析液含有作为渗透剂的物质，其基本上不渗透通过体外透析器的中空纤维膜的孔隙，优选分子量为约20,000至约100,000的渗透剂。 透析期间补充量的渗透剂减少或不需要。

公开(公告)号：US20020037329A1

公开(公告)日：2002-03-28

申请号：US09955248

申请日：2001-09-17

发明人： Leo Martis ,  Lee W. Henderson

IPC分类号： A61K033/00 ,  A61K031/70 ,  A61K031/19

CPC分类号： A61K33/14 ,  A61K33/00 ,  A61K45/06 ,  A61M1/287 ,  A61K33/10 ,  A61K31/7004 ,  A61K31/19 ,  A61K2300/00

摘要： A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g., pH of 7.0 to 7.4, and contains bicarbonate at a concentration that is found in blood involved in Additionally, the solution contains carbon dioxide at a partial pressure that is similar to partial pressure of carbon dioxide found in the blood capillaries. The peritoneal dialysis solution also contains a weak acid with a pKa of less than 5.0.

摘要翻译： 腹膜透析液，其生物化学平衡，以更生理的方式纠正与慢性肾衰竭相关的代谢性酸中毒。 腹膜透析溶液具有生理pH，例如pH7.0-7.4，并含有与血液相关的浓度的碳酸氢盐。此外，该溶液含有二氧化碳，分压与二氧化碳分压相似 发现于毛细血管。 腹膜透析液还含有pKa小于5.0的弱酸。

公开(公告)号：US06277815B1

公开(公告)日：2001-08-21

申请号：US09183225

申请日：1998-10-30

申请人： Thomas Knerr

发明人： Thomas Knerr

IPC分类号： A61K3800

CPC分类号： A61M1/287 ,  A61K33/14 ,  A61M1/3458 ,  A61K33/10 ,  A61K31/7004 ,  A61K31/19 ,  A61K2300/00

摘要： A solution for peritoneal dialysis or for infusion comprises two single solutions which, after heat sterilization, are brought together and dispensed, with the first single solution containing calcium ions, additional electrolytic salts and glucose in an osmotically effective concentration and the second single solution containing bicarbonate and a weak acid with pKa

摘要翻译： 用于腹膜透析或输注的溶液包括两个单一溶液，其在热灭菌之后，与含有钙离子的第一单一溶液，额外的电解盐和葡萄糖具有渗透有效浓度并且含有碳酸氢盐的第二单一溶液 和pKa <5的弱酸。 为了提供生物相容性溶液，特别是用作腹膜透析溶液，将第一单一溶液用生理相容的酸酸化至pH低于3.2。 第二单一溶液的碳酸氢盐含量不超过10 mmol / l。

公开(公告)号：US20010009670A1

公开(公告)日：2001-07-26

申请号：US09060611

申请日：1998-04-15

发明人： KEVIN JON WILLIAMS

IPC分类号： A61K009/00

CPC分类号： A61K31/685 ,  A61K9/127 ,  A61K35/14 ,  A61K38/1709 ,  A61M1/16 ,  A61M1/1619 ,  A61M1/1654 ,  A61M1/28 ,  A61M1/287 ,  A61M1/3427 ,  A61M1/3437 ,  B82Y5/00 ,  C12Q1/60 ,  G01N2800/52 ,  Y10S514/824 ,  A61K2300/00 ,  A61K31/575

摘要： The present invention provides a pharmaceutical composition, kit, and method of forcing the reverse transport of cholesterol from peripheral tissues to the liver in vivo while controlling plasma LDL concentrations. The method includes the step of administering a therapeutically effective amount of a multiplicity of large liposomes comprised of phospholipids substantially free of sterol for a treatment period. The method optionally includes the step of periodically assaying plasma LDL concentrations with an assay during the treatment period to assess plasma atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile, and adjusting the administration in response to said profile. The large liposomes are dimensioned larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver so that the liposomes are too large to readily penetrate the fenestrations. The therapeutically effective amounts are in the range of about 10 mg to about 1600 mg phospholipid per kg body weight per dose. A pharmaceutical composition and related kit for mobilizing peripheral cholesterol and sphingomyelin that enters the liver of a subject consisting essentially of liposomes of a size and shape larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver is also provided.

公开(公告)号：US06079416A

公开(公告)日：2000-06-27

申请号：US60646

申请日：1998-04-15

申请人： Kevin Jon Williams

发明人： Kevin Jon Williams

IPC分类号： A61K9/127 ,  A61K35/14 ,  A61K38/02 ,  A61M1/16 ,  A61M1/28 ,  A61M1/34 ,  C12Q1/60 ,  G01N33/53 ,  A61B19/00

CPC分类号： A61K9/127 ,  A61K31/685 ,  A61K38/02 ,  A61M1/3427 ,  A61M1/3437 ,  A61M1/16 ,  A61M1/1654 ,  A61M1/28 ,  A61M1/287

摘要： A pharmaceutical composition, kit, and method of forcing the reverse transport of cholesterol from peripheral tissues to the liver in vivo while controlling plasma LDL concentrations. The method includes the step of administering a therapeutically effective amount of a multiplicity of large liposomes comprised of phospholipids substantially free of sterol for a treatment period. The method optionally includes the step of periodically assaying plasma LDL concentrations with an assay during the treatment period to assess plasma atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile, and adjusting the administration in response to said profile. The large liposomes are dimensioned larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver so that the liposomes are too large to readily penetrate the fenestrations. The therapeutically effective amounts are in the range of about 10 mg to about 1600 mg phospholipid per kg body weight per dose. A pharmaceutical composition and related kit for mobilizing peripheral cholesterol and sphingomyelin that enters the liver of a subject consisting essentially of liposomes of a size and shape larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver is also provided.

摘要翻译： 一种药物组合物，试剂盒和方法，用于在控制血浆LDL浓度的同时强制将胆固醇从外周组织逆向转运至肝脏。 该方法包括施用治疗有效量的由基本上不含固醇的磷脂组成的多个大脂质体的治疗期。 所述方法任选地包括在治疗期间通过测定来定期测定血浆LDL浓度的步骤，以评估血浆致动脉粥样化脂蛋白浓度并获得致动脉粥样化脂蛋白分布，并根据所述特征调整给药。 大脂质体的尺寸大于肝脏内肝内窦内膜层的开窗，使得脂质体太大而不能容易地穿透开窗。 治疗有效量在每剂量每kg体重约10mg至约1600mg磷脂的范围内。 还提供了用于动员进入受试者肝脏的外周胆固醇和鞘磷脂的药物组合物和相关试剂盒，其基本上由大小和形状的脂质体组成，其尺寸和形状大于肝内的肝窦状内皮层的开窗。